Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

AI Briefing

• – Dyne Therapeutics announces positive cardiopulmonary results from DELIVER trial of Z-Rostudirsen in DMD, showing improvement in heart and lung function beyond expected natural history declines.
• – The trial results demonstrate Z-Rostudirsen's potential to slow disease progression in patients with DMD.
• – These findings provide a significant step forward in the treatment of DMD and support the company's ongoing efforts to bring Z-Rostudirsen to patients.